Intercept Pharma (ICPT) Announces Dagmar Rosa-Bjorkeson to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Intercept Pharma (ICPT) Misses Q4 EPS by 11c, Revenues Miss
February 25, 2021 7:29 AM ESTIntercept Pharma (NASDAQ: ICPT) reported Q4 EPS of ($1.58), $0.11 worse than the analyst estimate of ($1.47). Revenue for the quarter came in at $83.27 million versus the consensus estimate of $85.01 million.
As we turn the page on 2020, I am proud of the Intercept teams efforts to... More
UPDATE: H.C. Wainwright Downgrades Intercept Pharmaceuticals (ICPT) to Sell
February 23, 2021 6:47 AM EST(Updated - February 23, 2021 7:01 AM EST)
H.C. Wainwright analyst Ed Arce downgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Neutral to Sell, PT $25.00.
The analyst comments "In short, we no longer believe a viable regulatory path for OCA exists in... More
Intercept Pharma (ICPT) Chief Medical Officer Jason Campagna Resigns to Pursue Other Opportunities
February 22, 2021 4:53 PM ESTIntercept Pharma (NASDAQ: ICPT) disclosed:
On February 18, 2021, Jason Campagna, M.D., Ph.D., notified Intercept Pharmaceuticals, Inc. (the Company) of his decision to resign from his position as the Companys Chief Medical Officer, effective March 5, 2021, in order to pursue other opportunities. Dr.... More
